We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Acal | LSE:ACL | London | Ordinary Share | GB0000055888 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 320.25 | 320.00 | 324.75 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jan 2020 to Jan 2025
Novartis AG (NVS) Chief Executive Daniel Vasella Thursday said the Swiss drugmaker hopes to buy a 52% stake in U.S. eyecare maker Alcon Inc. (ACL) from food giant Nestle SA (NESN.VX).
"Hopefully we will buy the remaining stake from Nestle - the future will tell," Vasella, speaking from New York, said on financial broadcaster CNBC.
Vasella deflected questions about potential deals amid major ones in the pharmaceutical industry such as Roche Holding AG's (ROG.VX) $46.8 billion takeover of Genentech Inc. (DNA), pointing to the purchase of an Alcon minority stake last April.
Broadcaster Web site: www.cnbc.com
-By Katharina Bart, Dow Jones Newswires; +41 43 443 8043; katharina.bart@dowjones.com
1 Year Acal Chart |
1 Month Acal Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
